Skip to main content
Skin Health and Disease logoLink to Skin Health and Disease
. 2021 Dec 16;2(1):e82. doi: 10.1002/ski2.82

A preliminary study of peripheral T‐cell subsets in porokeratosis patients with MVK or MVD variants

L Tao 1, Y K Huang 1,2, K X Yan 1, C H Li 3, L Shen 4, Z H Zhang 1,
PMCID: PMC9060116  PMID: 35665211

Abstract

Background

Porokeratosis (PK) is considered a skin‐specific autoinflammatory keratinization disease. Intriguingly, four causative genes of PK are in turn arranged in mevalonate pathway, with MVD variants being the commonest followed by MVK variants in a cohort of Chinese patients. Evidence indicates that mevalonate metabolites induce trained immunity in human monocytes and regulate T cells at multiple levels. Of note, γδT cells are dually regulated by intracellular and extracellular mevalonate metabolism.

Aims

To identify the possible differences in T‐cell between MVK or MVD variants from PK patients.

Materials & Methods

Targeted exome sequencing and exonic CNV screening were performed in 26 patients with PK. Sanger sequencing was used to validate all identified variants. Among them, 22 patients were identified with MVK or MVD variants. PBMCs from 22 PK patients and 27 normal controls (NCs) were analysed by flow cytometry for the frequencies of T cells subsets, including IFN‐γ‐, and TNF‐α‐producing T cells.

Results

There were 14 mutations identified in the 26 PK patients, including 6 novel mutations (MVK: c.118_226+1337dup, c.388_392delGATATinsC, c.613A>T, c.768G>C, and MVD: c.250C>T, c.988T>G). In contrast to NCs, significantly decreased frequencies of CD8+ and Vγ9Vδ2 T cells were observed in the PK patients with MVD variants. Moreover, it was found that dysregulated secretion of pro‐inflammatory cytokines by T cells in both PK patients with MVK and MVD variants.

Conclusions

Our findings enriched the Human Gene Mutation Databases and showed probable differences in peripheral T cells subsets between PK patients and controls.


graphic file with name SKI2-2-e82-g002.jpg

1. INTRODUCTION

As a skin‐specific autoinflammatory keratinization diseases (AIKDs), porokeratosis (PK, MIM 175800) is inherited in an autosomal dominant pattern, whose genetic causative factors are associated with the hyperactivation of innate immunity, mainly in the epidermis and upper dermis. 1 Intriguingly, four causative genes of PK are in turn arranged in mevalonate pathway, that is, mevalonate kinase (MVK), phosphomevalonate kinase (PMVK), mevalonate (diphospho) decarboxylase (MVD) and farnesyl diphosphate synthase (FDPS). 2 , 3 Among them, MVD variants are the commonest cause followed by MVK variants in a cohort of Chinese patients. 3 , 4 Notably, the patients with MVK variants generally showed the widest range of phenotypes in terms of both the number and the size of lesions. Giant plaque‐type PK ptychotropica (PPt) appears to be a unique phenotype associated with MVK variants. The lesions of MVD variants tend to be more homogeneous and superficial than those carrying MVK variants. The possible reason is that MVK and MVD deficiencies result in different metabolites of the mevalonate pathway. Generally, it is accepted that mevalonate metabolites regulate T‐cell at multiple levels. 5 Based on the previous findings, we hypothesized that T‐cell bearing heterozygous mutations in mevalonate pathway might be altered and involved in the autoinflammation of PK. The possible reason is that the different abnormal metabolic intermediates produced by MVK and MVD variants might have different effects on T‐cell activation and cytokine production. In this study, we preliminarily analysed the distribution and cytokine production of peripheral T‐cell subsets in PK patients with MVK or MVD genotype.

2. REPORT

The study was approved by the by the Scientific Ethical Committee of Fudan University, and all participants provided written informed consent. From 2018 to 2019, peripheral blood samples were collected from 26 patients with PK (13 males and 13 females; mean age 53 ± 3 years). They were diagnosed by at least two experienced dermatologists, based on both clinical features and histological examinations. In view of the family history, these patients were divided into 15 familial and 9 sporadic cases. In addition, blood samples were collected from 27 healthy adult individuals (9 males and 18 females: mean age 42 ± 2 years). We determined the genomic variations in the PK patients by targeted exome sequencing and CNV analysis. 3 As indicated in Table 1, 14 mutations were identified in MVK, PMVK and MVD, including four novel mutations in MVK (c.118_226+1337dup, c.388_392delGATATinsC, c.613A>T, c.768G>C) and two novel mutations in MVD (c.250C>T, c.988T>G) (Figures S1 and S2). The novel mutations found in this study were confirmed to be absent in both gnomAD Exomes and ExAC East Asian database. The commonest MVD mutation (c.746T>C) was identified in seven of the unrelated patients, accounting for 26.9% of 26 PK patients. No mutation was found in three sporadic PK patients.

TABLE 1.

Characterization of 14 variants identified in 21 of the 26 patients

No. Gene Locus reference genomic Mutation Exon Predicted protein alternation Mutation type ACMG CADD SIFT score POLY ‐PHEN score Mutation‐Taster score ExAc_EAS a GenomeAD_Exomes_EAS b Cases References
Familial (affected/ unaffected) Sporadic
1 MVK NM_000431.2 c.118_226+1337dup 2,3 p.? Duplication F‐2(1/0)
2 MVK NM_000431.2 c.388_392delGATATinsC 5 p.(Asp130Profs*2) Frameshift Substitution Pathogenic F‐9(1/0)
3 MVK NM_000431.2 c.451G>A 5 p.(Val151Met) Missense Likely pathogenic 5.9687 0.01 0.938 0.999995 F‐11(1/0) Zhang et al. 3
4 MVK NM_000431.2 c.613A>T 6 p.(Asn205Tyr) Missense Likely pathogenic 6.1694 0 1 1 F‐1(3/0)
5 MVK NM_000431.2 c.710C>A 8 p.(Thr237Asn) Missense Likely pathogenic 4.9806 0 0.992 0.999254 F‐14(1/0) Zhang et al. 3
6 MVK NM_000431.2 c.768G>C 8 p.(Lys256Asn) Missense Likely pathogenic 5.998 0.005 0.86 1 S‐4
7 MVK NM_000431.2 c.1039+2T>C 10 p.? Splice_Site Pathogenic 4.744 1 F‐8(1/0) Zhang et al. 2 , 3
8 MVK NM_000431.2 c.1126G>A 11 p.(Gly376Ser) Missense Likely pathogenic 5.6853 0 0.996 0.999999 F‐15(1/0) Zhang et al. 2 , 3
9 PMVK NM_006556.3 c.412C>T 4 p.(Arg138*) Nonsense Pathogenic 13.0376 1 0.735406 1 F‐6(1/0) Zhang et al. 3
10 MVD NM_002461.1 c.250C>T 3 p.(Arg84Trp) Missense Uncertain significance 3.1932 0.008 0.97 0.987 0.0002 0.0002 F‐7(1/0)
11 MVD NM_002461.1 c.383C>T 4 p.(Ala128Val) Missense Uncertain significance 5.6033 0 0.998 0.999994 0.0002 0.0001 S‐6 Zhang et al. 3
12 MVD NM_002461.1 c.746T>C 7 p.(Phe249Ser) Missense Likely pathogenic 5.2987 0 1 0.999989 0.0005 0.0002 F‐3(1/0); F‐4(1/0); F‐5(1/0); F‐10(1/0); F‐12(1/0); F‐13(1/0) S‐2 Zhang et al. 3 ; Li et al. 4 ; Leng et al. 6 ; Kubo et al. 7
13 MVD NM_002461.1 c.988T>G 8 p.(Phe330Val) Missense Uncertain significance −0.0172 0.001 0.009 1 S‐1
14 MVD NM_002461.1 c.1111_1113del 9 p.(Ile371del) In_Frame_Del Uncertain significance 0.0002 0.0001 S‐3; S‐5 Zhang et al. 3
a

Exome Aggregation Consortium_East Asian allele frequency.

b

The Genome Aggregation Database_Exomes_ East Asian allele frequency.

PBMCs from 22 PK patients with MVK or MVD variants and 27 normal controls (NCs) were analysed by flow cytometry for the frequencies of T‐cell subsets, including IFN‐γ‐, and TNF‐α‐producing T‐cells. As indicated in Figure 1, the PK patients with MVD variants exhibited a significant decrease in the frequencies of peripheral CD8+ and Vγ9Vδ2T cell in the CD3+ T‐cell subsets compared with that of the NCs (p = 0.0009 and p = 0.0216, respectively). Therefore, the PK patients with MVD variants had a correspondingly higher CD4/CD8 ratio compared to that of the NCs (p = 0.0006). In addition, we found that the percentages of total Vδ1+, Vδ1+Vγ9+ and Vδ1+Vγ9 T‐cells in the CD3+ T‐cell subsets remained unchanged in the PK patients with either MVK or MVD variants compared with that of the NCs (Figure S3). Figure 2 showed IFN‐γ production by CD8+ T‐cell was increased in PK patients with MVK variants compared with that of the NCs and PK patients with MVD variants (p = 0.0275 and p = 0.0301, respectively). Moreover, TNF‐α production by Vγ9Vδ2 T‐cell was significantly increased in the PK patients with MVD variants compared with that of the NCs and the PK patients with MVK variants (p = 0.0085 and p = 0.0432, respectively).

FIGURE 1.

FIGURE 1

Gating strategy for flow cytometry (a), representative flow cytometry analyses (b), and scatterplot graphs (c) showed the frequencies of CD4+, CD8+ and Vγ9Vδ2T cells in the CD3+ T‐cell subsets and the ratio of CD4+ T‐cell/CD8+ T‐cell

FIGURE 2.

FIGURE 2

Representative flow cytometry analyses (a) and scatterplot graphs (b) of TNF‐α and IFN‐γ production in CD4+, CD8+ and Vγ9Vδ2T cells in the PK patients with MVK and MVD variants. MVK, the PK patients with MVK variants (n = 10); MVD, PK patients with MVD variants (n = 12); NCs, normal controls (n = 27)

Different from the patients with MVK variants, we observed that there were significant decreases in percentages of both CD8+ and Vγ9Vδ2T cells in the CD3+ T cells subsets in those with MVD variants. A reduction in the number of peripheral γδT cells, along with the elevated numbers in the skin, has been reported in patients with psoriasis. 8 A possible explanation was that CD8+ and Vγ9Vδ2T cells might home to the skin in the PK patients with MVD variants. As for non‐conventional lymphocytes, human γδT cell acts as the first line of defence and bridge the innate and adaptive immune systems, representing <5% of peripheral T‐cell in the adult human peripheral blood. γδT cells are at the crossroads of autoinflammation and autoimmunity, which produce cytokines and chemokines to promote the development of mixed‐pattern immune‐mediated inflammatory diseases. 9 It is well established that multiple phosphorylated mevalonate metabolites are potent agonists of Vγ9Vδ2T cells. 5 As the major peripheral γδT‐cell subsets, Vγ9Vδ2T cells are dually regulated by intracellular and extracellular mevalonate metabolism. Moreover, the peripheral Vγ9Vδ2T cells from PK patients with MVD variants showed a higher proportion expressed TNF‐α compared with NCs. In a different way, the dysregulated secretion of IFN‐γ by CD8+ T‐cells were observed in the PK patients with MVK variants. It is noteworthy that the IFN‐γ signalling for CD8+ T‐cells differentiation are delivered early in the immune response. The autocrine IFN‐γ signalling plays an important role in Th1 differentiation and CD8+ T‐cells cross‐priming. 10 , 11 It suggested that autoreactive CD8+ and γδT cells might play a critical role in the skin‐specific autoinflammatory PK. However, it was not known to what extent, if any, the pro‐inflammatory effects of these T‐cells might affect the pathogenesis of PK.

Danger signals from exogenous pathogens and endogenous keratinocyte death might trigger skin inflammation. Under certain circumstances, genetic defects in mevalonate pathway might block DNA degradation during epidermal cornification and develop a vertical ‘column’ of parakeratosis, histologically defined as a cornoid lamella (CL). In the context of a heterogeneous group of disease, CL unifies all phenotypes of PK. It is remarkable that non‐specific papillary dermal lymphocytic infiltration are frequently seen under the CL. 12 The local immune cell infiltration and chronic activation are involved in the pathomechanisms of PK. 13 The limitations of this study include a small sample size and the lack of comparison of CD8+T and γδT cells in the lesions of PK with MVK or MVD variants. Further investigation is necessary to explore resident T‐cells in the lesions of PK.

Taken together, our findings showed alterations in peripheral T‐cell subsets found in PK patients and provided the cues to further studies on autoreactive CD8+T and γδT cells in the pathogenesis of autoinflammatory keratinization.

CONFLICT OF INTEREST

The authors declared no conflicts of interest.

AUTHOR CONTRIBUTIONS

L. Tao: Data curation; Formal analysis; Investigation; Writing – original draft; Writing – review & editing. K. X. Yan: Resources. C. H. Li: Formal analysis; Software; Validation. L. Shen: Conceptualization; Data curation; Formal analysis; Investigation; Supervision. Z. H. Zhang: Conceptualization; Funding acquisition; Investigation; Supervision; Validation; Writing – original draft; Writing – review & editing.

Supporting information

Supporting Information S1

ACKNOWLEDGEMENTS

We thank all patients and family members who participated in this study. This work was supported by the grants from National Natural Science Foundation of China (Nos. 81673073, 81974471).

Tao L, Huang YK, Yan KX, Li CH, Shen L, Zhang ZH. A preliminary study of peripheral T‐cell subsets in porokeratosis patients with MVK or MVD variants. Skin Health Dis. 2022;2(1):e82. 10.1002/ski2.82

Lu Tao and Yike Huang contributed equally to this work.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are openly available at https://doi.org/10.17632/n93jd2znbm.1.

REFERENCES

  • 1. Takeichi T, Akiyama M. Familial or sporadic porokeratosis as an autoinflammatory keratinization disease. J Dermatol. 2019;46:e125–6. [DOI] [PubMed] [Google Scholar]
  • 2. Zhang SQ, Jiang T, Li M, Zhang X, Ren YQ, Wei SC, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet. 2012;44:1156–60. [DOI] [PubMed] [Google Scholar]
  • 3. Zhang Z, Li C, Wu F, Ma R, Luan J, Yang F, et al. Genomic variations of the mevalonate pathway in porokeratosis. Elife. 2015;4:e06322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Li M, Li Z, Wang J, Ni C, Sun Z, Wilson NJ, et al. Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis. J Eur Acad Dermatol Venereol. 2016;30:1512–17. [DOI] [PubMed] [Google Scholar]
  • 5. Thurnher M, Gruenbacher G. T lymphocyte regulation by mevalonate metabolism. Sci Signal. 2015;8:re4. [DOI] [PubMed] [Google Scholar]
  • 6. Leng Y, Yan L, Feng H, Chen C, Wang S, Luo Y, et al. Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis. J Dermatol. 2018;45(7):862–6. [DOI] [PubMed] [Google Scholar]
  • 7. Kubo A, Sasaki T, Suzuki H, Shiohama A, Aoki S, Sato S, et al. Clonal expansion of second‐hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes. J Invest Dermatol. 2019;139(12):2458–66. [DOI] [PubMed] [Google Scholar]
  • 8. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N, et al. Identification of a novel proinflammatory human skin‐homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol. 2011;187:2783–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17:585–95. [DOI] [PubMed] [Google Scholar]
  • 10. Sabat R, Wolk K, Loyal L, Döcke WD, Ghoreschi K. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41:359–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Boehncke WH, Brembilla NC. Autoreactive T‐lymphocytes in inflammatory skin diseases. Front Immunol. 2019;10:1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Biswas A. Cornoid lamellation revisited: apropos of porokeratosis with emphasis on unusual clinicopathological variants. Am J Dermatopathol. 2015;37:145–55. [DOI] [PubMed] [Google Scholar]
  • 13. Matsuyama K, Mizutani Y, Takahashi T, Shu E, Kanoh H, Miyazaki T, et al. Enhanced dendritic cells and regulatory T cells in the dermis of porokeratosis. Arch Dermatol Res. 2017;309:749–56. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information S1

Data Availability Statement

The data that support the findings of this study are openly available at https://doi.org/10.17632/n93jd2znbm.1.


Articles from Skin Health and Disease are provided here courtesy of Oxford University Press

RESOURCES